2 results
Approved WMOPending
This study will provide an estimate of basic PK parameters for guadecitabine, an assessment of the routes and rates of elimination of radioactivity, and identification of metabolites and metabolic pathways.
Approved WMOPending
Main Phase:To demonstrate the superiority of medium-dose BDP/FF/GB pMDI compared to high-dose BDP/FF pMDI in terms of the proportion of subjects exhibiting on average NPAL over 26 weeks of treatment in the study sub-population with PAL at screening…